Bibliografía del artículo
1. Gilroy JJ, James RA. Optimizing somatostatin analog therapy in acromegaly: long-acting formulations. Treat Endocrinol 1:149-54, 2002.
2. Ferone D, Colao A, Van der Lely AJ, Lamberts SW. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs Aging 17:81-92, 2000.
3. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JAH, Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563, 2002.
4. Donangelo I, Melmed S. Treatment of acromegaly: future. Endocrine 28:123-8, 2005.
5. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90(8):4465-73, 2005.
6. Resmini E, Murialdo G, Giusti M, Boschetti M, Minuto F, Ferone D. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. J Endocrinol Invest 28:166-169, 2005.
7. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A. Consensus statement: medical management of acromegaly. Eur Journal of Endocrinology 153:737-740, 2005.
8. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D. Rapid pituitary tumor shrinkage with dissociation between anti-proliferative and anti-secretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592-9, 2007.
9. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-403, 2006.
10. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-63, 2005.
11. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc 80:502-6, 2005.
12. Janson ET. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. J Endocrinol Invest 28:137-40, 2005.
13. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966-73, 2004.
14. Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M, degli Uberti EC. Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary 9:27-34, 2006.
15. Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta 1616:1-84, 2003.
16. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688-1696, 1996.
17. Lamberts SWJ, Reubi JC, Krenning EP. The role of somatostatin analogs in the control of tumor growth. Semin Oncol 21:61-64, 1994.
18. Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol 13:82-90, 1999.
19. García de la Torre N, Wass JAH, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 57:425-441, 2002.
20. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102(1):61-85, 2004.
21. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 86:2976-81, 2001.
22. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397-403, 2006.
23. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A. Consensus statement: medical management of acromegaly. Eur Journal of Endocrinology 153:737-740, 2005.
24. Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, Ferone D, Barreca A. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute post-glucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf) 61:138-144, 2004.
25. Giustina A, Barkan, A Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 8:526-9, 2000.
26. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85:781-92, 2000.
27. Hofland LJ, Lamberts SW. Somatostatin receptors in pituitary function, diagnosis and therapy. Front Horm Res 32:235-52, 2004.
28. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 88:4239-4245, 2003.
29. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P. BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86:140-5, 2001.
30. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545-52, 2002.
31. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-7, 2000.
32. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-9, 2000.
33. Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29:826-30, 2006.